19 April 2021 - The emergence of affordable Chinese immune checkpoint inhibitors is drawing attention to whether they will change the landscape of the global pharmaceutical market.

Chinese pharmaceutical products have a strong price advantage. Local pharmaceutical products in China are promoted through the National Reimbursement Drug List in China, making Chinese drugs dramatically discounted compared to global brands. Therefore, Chinese drugmakers can generate substantially high profits in China.

Read Korea Biomedical Review article